Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (213)	11/25/1997 12:35:00 AM
From: J Bertrand	Read Replies (1) \| Respond to of 305

Dear friends, Can anyone tell me if Amerindo still owns some of the stock? Thanks Jeff

To: Bosco who wrote (213)	11/25/1997 8:34:00 AM
From: Paul Getman	Read Replies (1) \| Respond to of 305

Bosco, Your comments are very creative and thoughtful, but I have a different interpretation about IMUL's press release. I've watched the biotechs pretty carefully now for several years. My interpretation is that IMUL realized it didn't have the cash to carry through on its Allervax program (I did these calculations for the board some time ago showing that IMUL, despite its cash hoard needed to raise money in a couple of years). Also, IMUL obviously had some technical doubts about its Allervax program and/or its ability to show efficacy. (Recall that none of the trial results to date were clear cut.) The paragraph you quoted about the company's going forward with its vaccines for abuse and "recombinant proteins directed to the diagnosis and treatment of allergic diseases" (whatever that means) isn't very convincing. Recall that one of Marr's first moves was to shelve the cocaine vaccine in favor of concentrating on the Allervax program. And I've never seen any mention before of IMUL's pursuing serious work on anything other than MS and Allervax, so I doubt there's anything else there to commercialize. In fact, I believe they will be laying off most of the technical staff shortly to conserve cash--else, it will be awfully crowded in their HQ if they're putting most of it up for lease. (I've been there--it's not that big to begin with.) So, IMUL, through its press release, is putting itself up for sale. Everything else in the press release is pure fluff. Ask yourself: why else would they be engaging H&Q? There's no other reason. They're out there, along with Autoimmune and a few others, cash rich and product poor, available to another Mass. biotech that wants their facilities. Paul